Used as a positive allosteric modulator of the mu-opioid receptor, BMS-986122 enhances the activity of endogenous opioids without directly activating the receptor itself. This property makes it a candidate for pain management with potentially reduced side effects compared to traditional opioid agonists, such as respiratory depression and tolerance. It is primarily investigated in preclinical research to understand opioid receptor modulation and to develop safer analgesic therapies. Its selective action on the mu-opioid receptor’s allosteric site may lead to improved pain control with lower abuse liability.